King Pharmaceuticals KG Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.58M— | —— | —— | —— | $34K— | ||
| $3.16M-7.6% | $3.42M-50.0% | $6.84M+182% | $2.42M— | $0— | ||
| $10.19M-0.1% | $10.21M-41.5% | $17.45M+214% | $5.56M+561% | $841K-31.1% | ||
| $11.74M-2.6% | $12.06M+11.8% | $10.78M+112% | $5.08M+344% | $1.14M+1.3% | ||
| -$1K-102% | $48K+300% | -$24K— | $0— | $0— | ||
| $1.34M+231% | $405K-92.6% | $5.49M+419% | $1.06M— | $0— | ||
| -$6.95M— | —— | -$4.06M-106% | $70.43M+23,420% | -$302K— | ||
| $6K— | —— | $7K+133% | $3K-96.7% | $92K+207% | ||
| -$7.43M— | —— | -$5.05M-107% | $69.93M+17,848% | -$394K— | ||
| -72.9%— | —— | -29%-1,288pp | 1,258.8%+1,306pp | -46.8%— | ||
| -$0.90— | —— | -$4,088,000.00-106% | $70,422,000.00+50,301,428,671% | -$0.14— | ||
| -$0.06+100.0% | -$6,000.49— | $0.00-100% | $1,000.00— | $0.00— | ||
| -$0.96— | —— | -$0.65-104% | $15.05+10,850% | -$0.14— | ||
| -$0.96— | —— | -$0.65-104% | $15.05+10,850% | -$0.14— | ||
| 7.8M+35.3% | 5.7M-26.0% | 7.7M+67.0% | 4.6M+68.6% | 2.7M0.0% | ||
| 7.8M+35.3% | 5.7M-26.0% | 7.7M+67.0% | 4.6M+68.6% | 2.7M0.0% | ||
| $503K-77.1% | $2.2M-25.3% | $2.94M+122% | $1.33M— | $0— | ||
| $2.66M+115% | $1.24M-67.2% | $3.76M+243% | $1.1M— | $0— | ||
| $2.65M+118% | $1.22M-68.7% | $3.9M+256% | $1.1M— | $0— | ||
| $2.26M-50.4% | $4.55M-56.3% | $10.41M+275% | -$5.96M— | $0— | ||
| -$0.9— | —— | -$0.53-103% | $15.16+10,929% | -$0.14— | ||
| -$0.9— | —— | -$0.53-103% | $15.16+10,929% | -$0.14— | ||
| -$0.06+70.0% | -$0.2-66.7% | -$0.12-9.1% | -$0.11— | $0— | ||
| $17.14M— | —— | $21.5M— | —— | $1.14M+1.3% | ||
| -$681K+33.0% | -$1.02M-35.8% | -$748K+36.9% | -$1.19M— | $0— | ||
| $1.47M+44.6% | $1.02M-40.7% | $1.72M+336% | $394K— | $0— | ||
| $9K-97.0% | $299K+111% | -$2.82M-201% | $2.78M+15,339% | $18K-76.9% | ||
| $3.12M+0.5% | $3.1M+91.5% | $1.62M+198% | $544K-32.6% | $807K-31.4% | ||
| $2.23M— | —— | $2.85M— | —— | $0— | ||
| -$6.95M— | —— | -$4.09M-106% | $70.42M+17,974% | -$394K— | ||
| $5.56M+111% | -$50.55M-316% | $23.36M+169% | $8.7M+3,650% | -$245K+37.6% | ||
| -$16.74M-138% | -$7.04M+68.2% | -$22.16M+11.7% | -$25.09M— | $0— | ||
| -$139K-117% | $810K+30.9% | $619K— | —— | $270K+174% | ||
| $3.9M-7.6% | $4.22M+2.2% | $4.13M+172% | $1.52M— | $0— | ||
| $2.58M-21.5% | $3.28M-6.0% | $3.49M+128% | $1.53M+4,403% | $34K-20.9% | ||
| -$486K— | —— | —— | -$40M— | $0— | ||
| $53M+24.6% | $42.53M+165% | $16.08M-81.8% | $88.33M— | $0— | ||
| -$15.13M+77.0% | -$65.71M-578% | -$9.7M+51.2% | -$19.86M-2,167% | -$876K-307% | ||
| -$14.45M+77.7% | -$64.69M-623% | -$8.95M+52.1% | -$18.68M-2,032% | -$876K-307% | ||
| $7K+133% | $3K-82.4% | $17K+1,600% | $1K— | $0— | ||
| $474K+0.6% | $471K+313% | $114K-76.7% | $490K— | $0— | ||
| $2.65M+118% | $1.22M-68.7% | $3.9M+256% | $1.1M— | $0— | ||
| $1.23M-34.8% | $1.89M+104% | $924K+555% | $141K— | $0— | ||
| $38.12M-19.9% | $47.6M+504% | $7.88M+7.7% | $7.31M— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is King Pharmaceuticals's revenue?
- King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.
- Is King Pharmaceuticals profitable?
- King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.
- What is King Pharmaceuticals's earnings per share?
- King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.
- Where does King Pharmaceuticals's income statement data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
